Issue #015Policy & Access6 min readNovember 6, 2026

COMP360 could launch in 2027. The trained workforce to deliver it is still being built

The NDA is on track for Q4 and launch is guided for 2027. The harder question at FDA's hearing was who will deliver the treatment.

Jama Pitman
Jama Pitman
CEO, Rose Hill Life Sciences
The Rose Hill Review
015

THE DISPATCH

Compass Pathways expects to complete its rolling New Drug Application for COMP360 synthetic psilocybin in treatment-resistant depression in the fourth quarter of 2026. It holds a National Priority Voucher that could shorten FDA's review to one to two months, and it has guided to a US commercial launch in the first half of 2027, subject to approval and DEA rescheduling.¹ With FDA's review of efficacy still ahead, investor attention has begun to extend to a second question: how the treatment would be delivered at scale if approved. That was also the main theme of FDA's first public hearing on psychedelic therapeutics on September 14, where testimony focused less on efficacy and more on training, staffing, and reimbursement.² ³

In this issue:

→ What Compass has disclosed about approval timing, cash, and the clinics it expects to use

→ Why workforce training became the main theme at FDA's hearing, and what Compass is funding to address it

→ A record financing quarter, the VA's largest psilocybin trial, and the step after FDA approval


THE SCIENCE

The regulatory picture is now specific. Compass began its rolling NDA submission with FDA agreement in April 2026 and says final submission is expected in Q4.¹ It reported $433 million in cash at the end of June, which it says funds operations into 2028, beyond the expected launch.¹ Speaking to investors at a Deutsche Bank conference on September 17, management said roughly 8,000 interventional psychiatry clinics already deliver supervised, multi-hour treatments, mostly esketamine (Spravato), and that the number is growing by about 500 sites a quarter. They also said they expect a monitoring period of about six hours per COMP360 session, compared with two hours for esketamine, and that Category III CPT codes for psychedelic medication therapy, in effect since January 2024, are already in place.⁴ These are company statements, not independent figures, but they describe the business model plainly: COMP360 is being positioned to run through clinics that already exist, not through a new category of treatment center.

The constraint is people. A six-hour supervised session takes three times the clinician time of an esketamine visit, and it requires staff trained in preparation, in-session monitoring, and follow-up care. On September 10, Compass named five recipients of a US grant program to develop post-approval provider training for COMP360: CME Outfitters, Emory University, Fluence International, the Integrative Psychiatry Institute, and Strata Mental Health Solutions.⁵ Steve Levine, Compass's Chief Patient Officer, described COMP360 as "a distinctly new approach to TRD management" that requires "a workforce with the right skills and capabilities."⁵ Grant amounts were not disclosed.

FDA's hearing four days later made the same point from the regulator's side. According to a summary of the testimony, speakers called for standardized, competency-based training across the full treatment process, clearly defined roles for nurses, facilitators, and pharmacists, infrastructure that can expand to future indications, and use of what Oregon, Colorado, and Australia have already learned.³ Reimbursement, regulatory barriers, and stigma were raised as the main obstacles to patient access. The written comment period closed on October 5.²

For investors, the practical point is that approval is a necessary milestone but not the one that determines revenue. The rate at which trained staff, clinic capacity, and payer coverage come online will decide how quickly an approved drug reaches patients, and that timeline is less certain than the regulatory one.


THE STORY

Among those who testified on September 14 was John Eaton, Vice President of Complex Care at the Wounded Warrior Project, which has funded research combining evidence-based treatment with psychedelic-assisted therapy for five years. "What we're doing today is to look at, you know, what is the appropriate dose of psychedelic medication? What is the indication? Who's a good fit? Also, what is the type of follow-on care that's necessary?" he told local reporters.⁶ His questions are the same ones clinics, payers, and training programs will need to answer once a drug is approved. A veterans' organization raising them at an FDA hearing is a sign that delivery questions are now being asked alongside the efficacy questions FDA has yet to settle.

Rose Hill Life Sciences is a psychedelic research organization, specializing in the production and research of Psilocybe cubensis operating at the intersection of science and therapeutic integration.


ON OUR RADAR

① A Record Quarter for Psychedelic Financing

Psychedelic Alpha counted more than $1 billion raised across ten financing events in Q2 2026, a quarterly record. The largest was an $805 million raise by Definium Therapeutics (formerly MindMed) after positive Phase 3 depression results for its LSD formulation, followed by $117.5 million for GH Research.⁷ Definium has since reported two positive Phase 3 trials in generalized anxiety disorder and plans an NDA filing in the first half of 2027.⁸

② The VA's Largest Psilocybin Trial Is Underway

The Department of Veterans Affairs is running PIVOT, a double-blind, placebo-controlled trial of pharmaceutical-grade psilocybin in at least 240 veterans with treatment-resistant depression, some with co-occurring PTSD, across five VA medical centers, with work planned through June 2031.⁹ For payers and health systems, data from inside the VA may carry more weight than industry trials.

③ After FDA Approval, the DEA Step

Psilocybin is currently Schedule I. Compass told investors that after FDA approval, rescheduling follows at the federal and then state level.⁴ Federal law requires the DEA to issue an interim final rule scheduling a newly approved drug within 90 days of the later of FDA approval or HHS's scheduling recommendation (21 U.S.C. § 811(j)), and many states then reschedule separately.¹⁰ That sequence is one reason the company guides to launch in the first half of 2027 rather than immediately after an approval decision.


YOU ASKED

Q: "If approval is on track, why should an investor care about training programs and CPT codes?"

Because they decide how fast an approved drug turns into treated patients. Esketamine is the closest precedent: it was approved in 2019 for treatment-resistant depression and required in-clinic administration with monitoring, and its adoption depended on clinics setting up capacity and payers agreeing to cover the time involved. COMP360 would face the same constraints with a longer session. The useful things to track after approval are the number of certified sites, the availability of trained staff, and whether payers move the new CPT codes from Category III, which are tracking codes, to Category I, which support routine reimbursement. Compass has said it intends to pursue that change after approval.⁴ Those indicators will say more about the launch than the approval date itself.


This week's takeaway: Compass expects to complete its COMP360 NDA in Q4 2026 and guides to a 2027 launch, with cash into 2028. The main open question, raised by both the company and FDA's September hearing, is whether enough trained clinicians and reimbursed clinic time will be available to deliver a six-hour supervised treatment at scale.

A question worth sitting with: if the first psilocybin approval arrives before the trained workforce does, who will patients reach first: the clinics that are ready, or the ones that are fastest?

Read the company's disclosure directly: Compass Pathways: Second Quarter and First Half 2026 Financial Results and Business Highlights

If someone in your network is building thesis in psychedelic medicine and not yet reading The Rose Hill Review, forward this. The field is moving faster than most people realize.

— Jama Pitman

Jama Pitman

CEO, Rose Hill Life Sciences

Advancing the development of novel psychedelic-based therapeutics


FOOTNOTES

¹ Compass Pathways. "Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights." August 5, 2026. https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Second-Quarter-and-First-Half-2026-Financial-Results-and-Business-Highlights/default.aspx

² U.S. Food and Drug Administration. "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing, 09/14/2026." https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/considerations-potential-future-therapeutic-use-psychedelic-drugs-public-hearing-09142026

³ UBC. "Summary and Key Takeaways from FDA's September 2026 Public Hearing on Psychedelic Drugs." https://ubc.com/insights/summary-and-key-takeaways-from-fdas-september-2026-public-hearing-on-psychedelic-drugs/

⁴ Investing.com. "COMPASS Pathways at Deutsche Bank summit: launch nears for COMP360." September 17, 2026. https://www.investing.com/news/transcripts/compass-pathways-at-deutsche-bank-summit-launch-nears-for-comp360-93CH-4906106

⁵ Compass Pathways. "Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training." September 10, 2026. https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-U-S--Grant-Program-Recipients-for-the-Development-of-Post-Approval-COMP360-Provider-Training/default.aspx

⁶ News4JAX. "'Promising results': Jacksonville veterans weigh in on psychedelic-assisted PTSD treatment at FDA hearing." September 14, 2026. https://www.news4jax.com/news/local/2026/09/14/promising-results-jacksonville-veterans-weigh-in-on-psychedelic-assisted-ptsd-treatment-at-fda-hearing/

⁷ Psychedelic Alpha. "Psychedelic Funding Update: Q2 2026." July 24, 2026. https://psychedelicalpha.com/news/psychedelic-funding-update-q2-2026/

⁸ Definium Therapeutics. "Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder." September 14, 2026. https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder

⁹ Military Times. "Major VA study to examine effectiveness of psilocybin on depression, PTSD." August 6, 2026. https://www.militarytimes.com/news/2026/08/06/major-va-study-to-examine-effectiveness-of-psilocybin-on-depression-ptsd/

¹⁰ 21 U.S.C. § 811(j). https://www.law.cornell.edu/uscode/text/21/811


The Rose Hill Review

Jama Pitman
Jama Pitman
CEO, Rose Hill Life Sciences

Advancing the development of novel psychedelic-based therapeutics.

Enjoy this issue?

Get this analysis every week, in your inbox.

Clinical science, veteran data, and honest coverage of psychedelic medicine, every Tuesday.

Browse all issues